Revenue
No reported data
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Research & development | $118.4M | $119.0M | $87.5M | $65.1M | $44.0M | $23.4M | $12.6M |
| Operating expenses | $179.0M | $178.2M | $136.9M | $110.4M | $83.2M | $51.4M | $21.2M |
| Operating income | −$179.0M | −$178.2M | −$136.9M | −$110.4M | −$83.2M | −$51.4M | −$21.2M |
| EBITDAderived | — | — | −$136.7M | −$110.1M | −$83.0M | −$51.3M | −$21.1M |
| Net income | −$287.9M | −$155.1M | −$118.5M | −$91.5M | −$71.7M | −$60.3M | −$19.6M |
| Basic EPSper diluted share | -$3.08 | -$2.30 | -$2.32 | -$2.16 | -$1.79 | -$3.55 | -$2.62 |
| Diluted EPSper diluted share | -$3.08 | -$2.30 | -$2.32 | -$2.16 | -$1.79 | -$3.55 | -$2.62 |
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Oct 24, 2024Form 4 | Malievskaia EkaterinaTenPercentOwner | SellOrdinary Shares · indirect | 776.6K | — | — | 3.16M |
| Oct 24, 2024Form 4 | Malievskaia EkaterinaTenPercentOwner | SellOrdinary Shares | 776.6K | — | — | 3.15M |
| Oct 24, 2024Form 4 | Goldsmith George JayTenPercentOwner | SellOrdinary Shares · indirect | 776.6K | — | — | 3.15M |
| Oct 24, 2024Form 4 | Goldsmith George JayTenPercentOwner | SellOrdinary Shares | 776.6K | — | — | 3.16M |
| Sep 26, 2024Form 4 | ATAI Life Sciences AG +1TenPercentOwner | SellOrdinary Shares · indirect | 2.66M | $6.05 | $16.09M | 6.91M |